Clinical results from SpectraCure’s fourth patient treatment
The fourth patient in the clinical phase 1 trial that SpectraCure is running for treatment of patients with recurrent prostate cancer was conducted, as previously communicated, on February 22th. The treatment was performed using the method for photodynamic therapy (PDT) that SpectraCure has developed. From the MRI of the prostate acquired a week after treatment, it is clear that the procedure has resulted in a clear effect. The images show a clear treatment result and intended change in the prostate gland and tumor area as a result of the PDT treatment. – We see excellent tissue